The use of tumoral markers and especially of BHCG and AFP in the diagnosis, staging and follow-up of patients affected by testicle germinai neoplasms is now widespread. Nevertheless, controversies stili exist in each one of these fields. Especially for clinical staging, high percentages of understaging of stage I tumours are reported in literature with considerable effects on therapeutical indications and prognosis. The Authors attempt a criticai review on the use of markers for diagnosis and staging of testicular neoplasms based upon their own experience of 79 cases over a 14-year period.
JavadpourN.: The role of biologic tumour markers in testicular cancer. Cancer, 45: 1755–1761, 1980.
2.
KleinE.A.: Tumour markers in testis cancer. Urol. Clin. North Am., 20 (1): 67–73, 1993.
3.
BrewerJ.A., TankE.S.: Yolk sac tumours and alphaletoprotein in first year of life. Urology, 42 (1): 79–80, 1993.
4.
RichieJ.P.: Neoplasie del testicolo. In: WalshP.C., RelikA.B., StameyT.A., VaughanE.D.Jr.: Campbell's Urology, ed. 6, Verducci ed., Roma, 1993, pp. 1271–1317.
5.
FossaS.D., KleppO., PausE.: Neuron-specific enolase: a serum tumour marker in seminoma?Br. J. Cancer, 65: 297–299, 1992.
6.
GrossA.J., DieckmannK.P.: Neuron-specific enolase: a serum tumour marker in malignant germ-cell tumors?Eur. Urol., 24: 277–278, 1993.
7.
BoslG.J., DmitrovskyE., ReuterV.E.: Isochromosome of chromosome 12: a clinically useful marker for male germ cell tumours. J. Nall. Cancer. Inst., 24: 1874–1878, 1989.
8.
MarrinkJ., AndrewsP.W., van BlummenP.J., De JongH.J., SleijferD. Th., Schraffordt KoopsH., OosterhuisJ.W.: TRA-1-60: a new serum marker in patients with germ cell tumours. Int. J. Cancer, 49: 368–372, 1991.
9.
GiwercmannA., AndrewsP.W., JorgensenN., MullerJ., GraemN., SkakkebaekN.E.: Immunohistochemical expression of embrional marker TRA-1-60 in carcinoma in situ and germ cell tumours of the testis. Cancer, 72 (4): 1308–1314, 1993.
10.
LewisD.J., SesterhennI.A., McCarthyW.F., MoulJ.W.: Immunohistochemical expression of P53 tumour suppressor gene protein in adult germ cell testis tumours: clinical correlation in stage I disease. J. Urol., 152: 418–423, 1994.
11.
RichieJ.P.: Testis cancer-reduction in treatment morbidity with maintenance of treatment efficacy. J. Urol., 152: 431–432, 1994.
12.
RichieJ.P.: Diagnosis and staging of testicular tumours. In: SkinnerD.G., LieskovskyG.: Diagnosis and management of genitourinary cancer, Saunders Co., 1988, pp. 498–507.
13.
JavadpourN.: Current status of tumour markers in testicular cancer. Eur. Urol., 21 (suppl. 1): 34–36, 1992.
14.
StephensR.L., WilliamsonS.K.: Clinical Stage I testicular cancer: orchiectomy without node dissection. Ann. Int. Med., 109: 179–181, 1988.
15.
FreedmanL.S., FreedmanL.S., ParkinsonM.C., JonesW.G., OliverR.T., PeckhamM.J., ReadG., NewlandsE.S., WilliamsC.J.: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet, 2: 294–298, 1987.
16.
PizzocaroG., SalvioniR., AguzziE.: Pathological verification of retroperitoneal nodes in early stage nonseminomatous germ-cell tumours (NSGCT) of the testis. J. Urol., 143 (4), abstr. n. 829, 1990.
17.
MeLeodD.G., WeissR.B., StableinD.M., MuggiaF.M., PaulsonD.F., EllisJ.H., SpauldingJ.T., DonohueJ.P.for the Testicular Cancer Intergroup Study: Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J. Urol., 145: 1178–1183, 1991.
18.
SheinfeldJ.: Nonseminomatous germ cell tumours of the testis: current concepts and controversies. Urology, 44: 2–14, 1994.
